The BioFire® RP2.1 Panel Did Not Identify Concurrent Respiratory Virus Infection in Adults with Variable SARS-CoV-2 Disease Severity and Infection Duration
Table 2
COVID-19 severity and concurrent respiratory infections.
BioFire® testing
Disease severity
# of individuals
SARS-CoV-2 (+)
Other respiratory pathogens (+)
Cohort 1 (n = 122)
Cohort 21 (n = 23)
Cohort 1
Cohort 2
Cohort 1
Cohort 2
Asymptomatic
6 (4.9%)
9 (39.1%)
3 (50.0%)
8 (88.9%)
0 (0%)
0 (0%)
Mild
48 (39.3%)
7 (30.4%)
15 (31.3%)
7 (100%)
0 (0%)
1 (14.3%)
Moderate
33 (27.0%)
6 (26.1%)
22 (66.7%)
6 (100%)
0 (0%)
0 (0%)
Severe
35 (28.7%)
1 (4.3%)
27 (77.1%)
1 (100%)
0 (0%)
0 (0%)
1Five individuals declined to complete the symptom survey.